Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®
Paris, France - August 8, 2017 - Sanofi announced today that it filed a patent infringement suit against Merck Sharp & Dohme Corp. ("Merck") on August 8, 2017 in the United States District Court for the District of New Jersey. In its suit Sanofi alleges infringement of two patents.
The suit was triggered by a notification received from Merck in late June, in which Merck stated that it had filed an NDA (505(b)(2) New Drug Application) with FDA for an insulin glargine vial drug product. Merck also stated that its NDA included a paragraph IV certification challenging all of the Sanofi patents then listed in the FDA Orange Book for Sanofi's Lantus® and Lantus® SoloStar® products.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Contacts:
| Media Relations Ashleigh Koss Tel: +1 (908) 981-8745 Mobile: +1 (908) 205-2572 [email protected] | Investor Relations George Grofik Tel. +33 (0) 1 53 77 45 45 [email protected] |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/77fe10b9-ef21-49d6-82d8-04a6516ee80a
